Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Travere Therapeutics (NASDAQ:TVTX) in the last three months.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Analysts have recently evaluated Travere Therapeutics and provided 12-month price targets. The average target is $18.38, accompanied by a high estimate of $23.00 and a low estimate of $12.00. This upward trend is apparent, with the current average reflecting a 16.7% increase from the previous average price target of $15.75.

Decoding Analyst Ratings: A Detailed...